Table 1

Baseline characteristics of study participants, by 25(OH)D group

25(OH)D group, ng/mL


0-10

>10-≤20

>20-<30

≥30

Characteristic

(n = 40)

(n = 138)

(n = 50)

(n = 10)

P-value


Demographics

Age (yr)

55.0 ± 11.2

57.8 ± 11.8

58.8 ± 10.2

62.4 ± 11.3

0.21

Male, n (%)

26(65.0)

104(75.4)

38 (76.0)

8 (80.0)

0.57

Caucasian, n (%)

23 (57.5)

103 (74.6)

41 (82.0)

10 (100.0)

0.012

BMI (kg/m2)

32.1 ± 5.6

30.9 ± 6.9

29.5 ± 5.6

26.5 ± 4.6

0.066

Socio-economic status

Low social support, n (%)

11 (27.5)

20 (14.9)

3 (6.0)

0 (0)

0.023

No health insurance, n (%)

14 (35.0)

28 (20.9)

5 (10.4)

1 (10.0)

0.036

Lifestyle

Smoked within 1 month, n (%)

24 (60.0)

49 (35.5)

15 (30.0)

0(0)

<0.001

Leisure time activity, n (%)

0.047

Mainly sedentary

20 (50.0)

56 (40.9)

19 (38.0)

1 (10.0)

Mild exercise

13 (32.5)

49 (35.8)

11 (22.0)

3 (30.0)

Moderate exercise

6 (15.0)

27 (19.7)

17 (34.0)

4 (40.0)

Strenuous exercise

1 (2.5)

5 (3.6)

3 (6.0)

2 (20.0)

Geographical region, n (%)

0.79

Midwest

18 (56.3)

53 (45.3)

15 (34.1)

5 (62.5)

Northeast

3 (9.4)

15 (12.8)

5 (11.4)

0 (0)

Southeast

5 (15.6)

23 (19.7)

9 (20.5)

1 (12.5)

Southwest

4 (12.5)

22 (18.8)

12 (27.3)

2 (25.0)

West

2 (6.3)

4 (3.4)

3 (6.8)

0 (0)

Season, n (%)

0.064

Apr-Jun

1 (2.5)

1 (0.7)

0 (0)

0 (0)

Jul-Sep

10 (25.0)

56 (40.6)

24 (48.0)

7 (70.0)

Oct-Dec

29 (72.5)

81 (58.7)

26 (52.0)

3 (30.0)

Comorbidities, n (%)

Diabetes

13 (32.5)

41 (29.7)

8 (16.0)

2 (20.0)

0.21

Hypertension

26 (65.0)

89 (64.5)

33 (66.0)

6 (60.0)

0.99

Prior MI

2 (5.0)

36 (26.1)

9 (18.0)

2 (20.0)

0.019

CKD

5 (12.5)

4 (2.9)

2 (4.0)

1 (10.0)

0.06

Chronic heart failure

3 (7.5)

6 (4.3)

1 (2.0)

1 (10.0)

0.38

LVH on admission ECG, n (%)

7 (17.9)

9 (6.7)

4 (8.2)

0 (0)

0.18

Killip class on arrival, n (%)

0.35

I

36 (94.7)

128 (94.8)

43 (86.0)

9 (90.0)

II

2 (5.3)

4 (3.0)

5 (10.0)

1 (10.0)

III

0 (0)

2 (1.5)

2 (4.0)

0 (0)

IV

0 (0)

1 (0.7)

0 (0)

0 (0)

Rose dyspnea score

1.0 ± 0.9

0.9 ± 0.9

0.8 ± 0.8

0.6 ± 1.0

0.43

Final MI diagnosis, n (%)

0.36

STEMI

15 (37.5)

64 (46.4)

23 (46.0)

2 (20.0)

Non-STEMI

25 (62.5)

74 (53.6)

27 (54.0)

8 (80.0)

LV systolic function, n (%)

0.54

Normal

24 (61.5)

88 (63.8)

36 (72.0)

6 (60.0)

Mild

8 (20.5)

24 (17.4)

10 (20.0)

1 (10.0)

Moderate

4 (10.3)

16(11.6)

4 (8.0)

1 (10.0)

Severe

3 (7.7)

10 (7.2)

0 (0)

2 (20.0)

Laboratory values

Troponin I (ng/ml)

1.4 ±1.9

1.7 ± 1.8

1.6 ± 1.7

0.7 ± 1.2

0.3

Total Cholesterol (mg/dl)

150.6 ± 47

157.3 ± 29

150.5 ± 29

189.7 ± 47

0.011

HDL(mg/dl)

37.9 ± 10.6

38.4 ± 8.7

40.6 ± 10.7

43.1 ± 25.2

0.36

LDL (mg/dl)

92.2 ± 36.7

97.4 ± 25

90.4 ± 25.7

119.2 ± 42.8

0.032

Triglycerides(mg/dl)

153.2 ± 74

185.6 ± 145

143.6 ± 79

195.4 ± 169

0.17

Calcium (mg/dl)

8.9 ± 0.6

8.8 ± 0.6

9.0 ± 0.4

9.3 ± 0.6

0.038

Intact PTH (pg/ml)

59.8 ± 67.7

40.1 ± 28.1

32.8 ± 15.3

32.0 ± 26.5

0.004

Phosphate (mg/dl)

3.6 ± 0.7

3.5 ± 0.8

3.5 ± 0.7

3.7 ± 0.9

0.69

hs-CRP (mg/l)

5.2 ± 5.6

3.8 ± 5.3

3.8 ± 4.5

0.9 ± 0.8

0.12

eGFR, mL/min/1.73 m2

84.7 ± 28.1

88.3 ± 27.3

80.3 ± 18.9

80.1 ± 18.8

0.25

Medications

ACEI/ARB, n (%)

11 (27.5)

39 (28.3)

18 (36.0)

1 (10.0)

0.43

Diuretic, n (%)

9 (22.5)

31 (22.5)

15 (30.0)

10(10.0)

0.58

Omega-3 supplements, n (%)

3 (7.5)

31 (22.5)

18 (36.0)

5 (50.0)

0.002


Wetmore et al. BMC Research Notes 2011 4:542   doi:10.1186/1756-0500-4-542

Open Data